Evidence map›Paper›PMID 37734893›Full record

ArticleBMJ open2023

Quantifying the impact of taking medicines for primary prevention: a time-trade off study to elicit direct treatment disutility in the UK.

Alexander Thompson, Ji-Hee Youn, Bruce Guthrie, Robert Hainsworth, Peter Donnan, Gabriel Rogers, Daniel Morales, Katherine Payne

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Alexander ThompsonManchester Centre for Health Economics, The University of Manchester, Manchester, UK alexander.thompson@manchester.ac.uk.ORCID 0000-0003-4930-5107
Ji-Hee YounManchester Centre for Health Economics, The University of Manchester, Manchester, UK.
Bruce GuthrieAdvanced Care Research Centre, University of Edinburgh, Edinburgh, UK.ORCID 0000-0003-4191-4880
Robert HainsworthManchester Centre for Health Economics, The University of Manchester, Manchester, UK.ORCID 0000-0002-3475-800X
Peter DonnanDundee Epidemiology and Biostatistics Unit, University of Dundee, Dundee, UK.ORCID 0000-0001-7828-0610
Gabriel RogersManchester Centre for Health Economics, The University of Manchester, Manchester, UK.ORCID 0000-0001-9339-7374
Daniel MoralesDivision of Population Health Sciences, University of Dundee, Dundee, UK.
Katherine PayneManchester Centre for Health Economics, The University of Manchester, Manchester, UK.ORCID 0000-0002-3938-4350
University of Manchester · GBUniversity of Dundee · GBUniversity of Edinburgh · GB

Funding

Department of HealthWellcome TrustWellcome Trust 214588/Z/18/Z
6 · The paper itself

Abstract

backgroundDirect treatment disutility (DTD) represents an individual's disutility associated with the inconvenience of taking medicine over a long period of time.

objectivesThe main aim of this study was to elicit DTD values for taking a statin or a bisphosphonate for primary prevention. A secondary aim was to understand factors which influence DTD values.

methods

resultsA total of 879 respondents were included for analysis (514 for statins and 365 for bisphosphonates). The majority of respondents reported a disutility associated with medicine use. Mean DTD for statins was 0.034 and for bisphosphonates 0.067, respectively. Respondent characteristics including age and sex did not influence DTD. Experience of bisphosphonate-use reduced reported disutilities.

conclusionsStatins and bisphosphonates have a quantifiable DTD. The size of estimated disutilities suggest they are likely to be important for cost-effectiveness, particularly in individuals at low-risk when treated for primary prevention.

Indexed as

DementiaHydroxymethylglutaryl-CoA Reductase InhibitorsAdultCross-Sectional StudiesDiphosphonatesHumansState MedicineUnited KingdomDiphosphonatesHydroxymethylglutaryl-CoA Reductase InhibitorsCoronary heart diseaseHealth economicsPREVENTIVE MEDICINE

Identifiers

PMID37734893
PMCPMC10514632
OpenAlexW4386936361

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.